• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
PharmaHandbook: BRIC (Brazil, Russia, India, China) 2013 Edition - Product Image

PharmaHandbook: BRIC (Brazil, Russia, India, China) 2013 Edition

  • ID: 2614733
  • July 2013
  • Region: Brazil, China, India, Russia
  • 152 Pages
  • VOI Consulting, Inc

Brazil, Russia, India, China. They share an acronym and rapid growth rates but otherwise the Big 4 Emerging Markets don't have a lot in common. With extensive data and analysis on the structural, regulatory and commercial aspects of the biopharmaceutical markets in each country, pharmahandbook's 2013 BRIC report provides you with what you need to know in order to capitalize on these vitally important but complex and differentiated opportunities.

About this report

An “essential resource”, "invaluable", "extremely useful", "a wonderful source of information"…that's what customers in the international pharmaceutical industry have been saying about pharmahandbook since 2003.

Why you need it

The BRIC markets are essential for any pharmaceutical company that hopes to grow its business over the next five years. This pharmahandbook report shows you how to succeed in these important and challenging locations.

Overview

Calculation of GDP and National Healthcare Spending

Market Calculations

Time Considerations

Monetary Figures, Exchange Rates & Growth Calculations

BRAZIL 2013

Healthcare System

Pharmaceutical Market
- Market Profile and Structure
- Market Performance and Forecasts

Regulatory

Approval Procedures

Pricing

Payment
- New Health Technology Assessment (HTA) Body

Generics

R&D / Clinical Trials

Manufacturing

Distribution

Intellectual Property Issues
- New Patent Approval Mechanisms

Marketing

List of Figures

RUSSIA 2013

Major Events

Healthcare System
- Recent Health Reforms

Pharmaceutical Market
- Market Profile and Structure
- Market Segments
- Commercial (Private Outpatient / Out-of-Pocket) Market
- Public Drug Programs
- The Hospital Market
- Impact of Pharma 2020 Strategy and Related Laws
- Impact of 2012 Public Health Law
- Regional VEDs will Mean Greater Fragmentation
- Market Performance and Forecasts

Regulatory
- Regulatory Reorganization
- Official Pharmaceutical Lists

Approvals

Pricing
- Market Prices
- Price Control Regulations

Payment
- Public Subsidies
- 15% Local Manufacturing Advantage
- Private Expenditures

Generics

R&D / Clinical Trials
- Clinical Trial Regulations
- Steps and Issues Associated with New Clinical Trial Approval System
- Clinical Trial Environment
- Trends in Clinical Trial Activity
- Trial Approval Timelines
- Other Considerations

Manufacturing
- Pharma 2020 Strategy - Impact on Manufacturing

Distribution

Intellectual Property
- Impact of WTO Accession

Marketing
- Marketing Regulations
- Marketing Practices
- Impact of the Public Health Law on Marketing

List of Figures

INDIA 2013

Major Events

Healthcare System

Pharmaceutical Market
- Market Profile and Structure
- Market Performance and Forecasts

Regulatory

Approval Procedures
- Biosimilar Regulations
- Proposal to Restrict New Drug Approvals to Generic Names
- Reports of Lax Regulatory Oversight

Pricing
- Details of New Price Control System
- Proposals for Patented Medicine Price Controls

Payment

Generics

R&D / Clinical Trials
- Clinical Trial Regulations
- Clinical Trial Environment

Manufacturing

Distribution

Patent & Intellectual Property Issues
- Provisions of the Patent Law
- Lack of Data Exclusivity
- Recent Developments and Future Outlook

Marketing
- Marketing Practices

List of Figures

CHINA 2013

Healthcare System
- Health Reforms

Pharmaceutical Market
- Market Profile and Structure
- Product Segments
- Market Access
- Market Fragmentation
- Impact of 2009-2011 Health Reforms
- Market Performance and Forecasts

Regulatory

Approval Procedures
- Provisional vs. Final Standards

Pricing

Payment
- NRDL
- EDL
- Hospitals and Tendering Systems

Generics

R&D / Clinical Trials

Manufacturing

Distribution

Patent & Intellectual Property Issues
- The Monitoring Period
- Provisional vs. Final Standards
- Compulsory Licensing

Marketing
- Marketing Regulations
- Marketing Practices

List of Figures

About VOI Consulting, Inc.

About the Author

List of Figures

Brazil

List of Figures

Figure 1 - Population and Economic Statistics
Figure 2 - General Healthcare Statistics
Figure 3 - Demographic Profile
Figure 4A - Pharmaceutical Market Snapshot
Figure 4B - Pharmaceutical Market Snapshot
Figure 5 - 2011 Population and Pharmaceutical Spending by Region
Figure 6 - Share and Sales by Product Category (2007 to 2011)
Figure 7 - Pharmaceutical Sales in the Retail Pharmacy Sector 2003 to 2011
Figure 8 - Top 10 Companies by 2011 Sales in Retail, Generic, and Non-Retail Markets (Brazilian companies are shaded)
Figure 9 - Maximum Allowable Price Increases for Marketed Drugs (2010 to 2012)
Figure 10 - Expenditures by Public Sector Pharmaceutical Program (2008 to 2011)
Figure 11 - Generic Market Value and Volume (Pharmacy Channel, 2003 to 2012)
Figure 12 - Generic Share of Value and Volume (Pharmacy Channel, 2003 to 2012)
Figure 13 - Top 10 Generic Companies by 2011 Share (Brazilian companies are shaded)
Figure 14 - Brazil Clinical Trial Starts by Phase (Number and Global Share: 2006-2011)
Figure 15 - Top 25 Companies by Share of the Overall Market (2010 to 2011, Brazilian companies are shaded)
Figure 16 - Structure of Distribution Network
Figure 17 - Leading Pharmacies by 2010 Market Share
Figure 18 - Promotional Spending by Type 2009 to 2011

Russia

List of Figures

Figure 1 - Population and Economic Statistics
Figure 2 - General Healthcare Statistics
Figure 3 - Leading Causes of Death, Russia vs. U.S.
Figure 4 - Russia's Health Infrastructure
Figure 5 - Demographic Profile
Figure 6 - Pharmaceutical Market Snapshot
Figure 7 - Top 10 Company Market Share in Overall and Retail Segments H1 2011 v. H1 2012
Figure 8 - Population and Income by Geography
Figure 9 - 2011 Sales and Share by Market Segment (End-user Prices)
Figure 10 - First Half 2012 vs. First Half 2011 Sales and Share by Market Segment (End-user Prices)
Figure 11 - Key Characteristics by Market Segment (2011; End-user Prices)
Figure 12 - Top 10 Therapeutic Categories in Pharmacy Market by Share of Sales (Jan-Sep 2012)
Figure 13 - Top 10 Therapeutic Categories in Reimbursed Market (Jan-Sep 2012)
Figure 14 - Market Share of Top 10 Companies in Reimbursed Segment (Jan-Sep 2012)
Figure 15 - Top 10 Therapeutic Categories in Hospital Market (Jan-Sep)
Figure 16 -Market Share of Top 10 Companies in Hospital Segment (Jan-Sep 2012)
Figure 17 - Top 10 Regions in Reimbursed Segment (Jan-Sep 2012)
Figure 18 - Market Forecast by Segment 2012 to 2016 (Ex-Manufacturer Value)
Figure 19 - Description of Official Pharmaceutical Lists
Figure 20 - Approval Steps and Timeframes in the Post-Law on Circulation Environment
Figure 21 - 2011 and 2012 Average Price per Unit by Market Segment (End-user Prices)
Figure 22 - Clinical Trial Approvals 2004-2012
Figure 23 - Approved Clinical Trials by Type 2004 - H1 2012
Figure 24 - Indian Clinical Trial Starts by Phase (Number and Share: 2006-2012)
Figure 25 - Statutory versus Actual Clinical Trial Approval Timeframes (First Half 2012)
Figure 26 - Leading Domestic Manufacturers (Jan-Sep 2012)
Figure 27 - Leading National and Interregional Distributors
Figure 28 - Leading Wholesalers (2011 - Share of Direct Sales)
Figure 29 - Leading Pharmacy Chains (2011 - Share of Retail/Self-Pay Segment)
Figure 30 - Promotional Spending by Type 2011
Figure 31 - Top 10 Companies and Brands by Promotional Spending 2011

India

List of Figures

Figure 1 - Population and Economic Statistics
Figure 2 - General Healthcare Statistics
Figure 3 - Health Insurance Coverage by Scheme (Millions of People)
Figure 4 - Demographic Profile
Figure 5A - Pharmaceutical Market Snapshot
Figure 5B - Pharmaceutical Market Snapshot
Figure 6 - Pharmaceutical Markets by Location Type
Figure 7 - Sources of Pharmaceutical Market Growth 2007 to 2011
Figure 8 - Retail and Hospital Sales and Share 2006-2011
Figure 9 - Therapeutic Category Share of Market and Value Growth (Year-Ending Jun 2012 vs. Jun 2011)
Figure 10 - Indian Regulatory System
Figure 11 - Responsibilities of Central and State Drug Regulators
Figure 12 - DPCO History
Figure 13 - Indian Clinical Trial Starts by Phase (Number and Share: 2006-2011)
Figure 14 - Top 50 Companies by sales in Indian Outpatient Market (MAT Mar 2012)
Figure 15 - Structure of Distribution Network
Figure 16 - Price Build-up in Distribution Channel
Figure 17 - Promotional Spending by Type 2011
Figure 18 - Top 10 Companies and Brands by Promotional Spending 2011

China

List of Figures

Figure 1 - Population and Economic Statistics
Figure 2 - General Healthcare Statistics
Figure 3 - Health Insurance Coverage in China 2011
Figure 4 - Demographic Profile
Figure 5A - Pharmaceutical Market Snapshot
Figure 5B - Pharmaceutical Market Snapshot
Figure 6 - Chinese Cities by Tier
Figure 7 - Top 10 Pharmaceutical Companies (Q1 2012)
Figure 8 - Share of Market Value by Drug Type (Western Drugs: 2009-2011)
Figure 9 - Procedures and Timeframe for Market Access in China
Figure 10 - Drug Approval Procedures & Timing
Figure 11 - Generics Share of Market Value and Volume Forecasts (2010-2015)
Figure 12 - Clinical Trial Regulatory Approval Process
Figure 13 - Top 10 Pharmacy Chains 2011
Figure 14 - Promotional Spending by Type 2011
Figure 15 - Promotional Spending by Company 2011

Note: Product cover images may vary from those shown

ALSO AVAILABLE

RELATED PRODUCTS

Our Clients

Our clients' logos